AmirAli Talasaz - 01 May 2025 Form 4 Insider Report for Guardant Health, Inc. (GH)

Signature
/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz
Issuer symbol
GH
Transactions as of
01 May 2025
Net transactions value
-$5,936,572
Form type
4
Filing time
05 May 2025, 21:02:01 UTC
Previous filing
02 Apr 2025
Next filing
09 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Talasaz AmirAli Co-Chief Executive Officer, Director 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz 05 May 2025 0001753159

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Sale $861,275 -18,069 -0.78% $47.67 2,291,387 01 May 2025 Direct F1, F2
transaction GH Common Stock Sale $1,874,299 -38,477 -1.7% $48.71 2,252,910 01 May 2025 Direct F1, F3
transaction GH Common Stock Sale $2,213,711 -44,691 -2% $49.53 2,208,219 01 May 2025 Direct F1, F4
transaction GH Common Stock Sale $175,395 -3,445 -0.16% $50.91 2,204,774 01 May 2025 Direct F1, F5
transaction GH Common Stock Sale $90,131 -1,748 -0.08% $51.56 2,203,026 01 May 2025 Direct F1, F6
transaction GH Common Stock Sale $18,611 -354 -0.02% $52.57 2,202,672 01 May 2025 Direct F1, F7
transaction GH Common Stock Sale $703,151 -13,932 -0.63% $50.47 2,188,740 02 May 2025 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.18 to $48.175 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.185 to $49.16 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.06 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.405 to $51.34 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.43 to $51.76 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.46 to $52.75 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.84 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.